



OBIS Financial & Strategic Investment Series - 2027

Executive Synthesis & Strategic Investment Overview

Integrated Introduction to Valuation, Financing, Portfolio,
Intellectual Property and Strategic Collaboration



Executive Synthesis

The introductory document for the complete 2027 investor series: one concise view of value, capital, portfolio, IP, milestones and collaboration.

2027 EXECUTIVE POSITION

OBIS Innovation & Solutions Inc. enters the 2027 investment cycle as a newly incorporated New York corporation with a defined US\$1.2M seed objective, a flagship LPS™ commercial case, an SPI™ strategic model, a biotechnology platform architecture comprising 72 proposed products across six generations, a developing IP architecture, and a formula-driven Pre-Money Valuation of US\$5.448 billion.

2027 Investment Snapshot

Headline figures aligned with the current investor series.



Purpose of this synthesis

This document does not replace the nine specialized documents. It provides the reading architecture: what each document contributes, how the figures connect, where the principal value drivers sit, and which elements remain subject to final technical, financial, legal, regulatory or documentary validation.


The 2027 Investment Proposition

A flagship-to-platform thesis supported by defined capital, controlled disclosure and milestone-linked value creation.

Flagship commercial anchor LPS™ supplies the first focused commercial and health-economic reference case for the 2027 series.	High-impact program SPI™ provides an additional high-upside scenario architecture, with commercialization linked to evidence generation, development milestones, regulatory progression, and execution.
Platform breadth The current architecture of 72 proposed products across six generations creates diversification, licensing optionality and future program-generation capacity.	Capital with purpose The US\$1.2M seed round is directed toward corporate/IP readiness, proof-of-concept work, regulatory preparation and foundational execution.
Protected value perimeter Background IP, formula-level technical information and unrelated platform rights remain controlled and are not transferred by association.	Milestone-based value Value is expected to change as IP, reproducible evidence, regulatory clarity, external validation, partnering and manufacturability reduce uncertainty.
Current valuation reference The 2027 series currently communicates a formula-driven Pre-Money Valuation of US\$5.448 billion. This is a current model-derived standard—not a realized transaction price—and will be recalibrated when material evidence or assumptions change.	

2027 Value Architecture

Value is built from a flagship-to-platform structure, not from a single headline metric.



Series Architecture – Documents 1 to 9

The series is modular: each document answers a specific investor question while remaining linked to one controlled 2027 investment narrative.

Nine Documents. One Investment Logic.

The 2027 series moves from executive positioning to valuation, capital, IP and collaboration decisions.



Reading sequence

Start with Document 1 for the executive financial logic. Documents 2–4 establish flagship and portfolio economics. Document 5 states the valuation framework and current formula-driven value. Documents 6–7 translate that value into financing and milestones. Document 8 protects the proprietary perimeter. Document 9 defines how science, research, capital, licensing and institutional collaboration can be structured without blurring rights.

Flagship & Platform Economics

The 2027 series separates product-market scenarios from enterprise valuation and avoids double counting across programs and the wider platform.

LPS™ – flagship commercial reference

U.S. penetration	Projected users	Gross revenue	Modeled net
6%	20.04M	US\$3.006B	~US\$831.2M
12%	40.08M	US\$6.012B	~US\$1.662B
24%	80.16M	US\$12.024B	~US\$3.325B

Planning assumptions in the current 2027 model include US\$150 unit price, 60% COGS, 5% administrative cost and 21% corporate tax. These remain model inputs subject to validation.

SPI™ –2027–2034 scenarios

Scenario	Cumulative revenue	Cumulative modeled net	2034 revenue
Conservative	US\$4.46B	US\$-0.51B	US\$2.00B
Base	US\$22.89B	US\$4.99B	US\$11.75B
Transformational	US\$82.15B	US\$35.09B	US\$39.00B

Portfolio interpretation

The 72-product, six-generation platform is additional scientific, strategic and transaction optionality. It is not valued by multiplying candidate count by a uniform per-asset value, and LPS™/SPI™ economics should not be counted a second time at the portfolio level.

Commercial perimeter

OBIS Biotech™ is the principal commercial biotechnology platform for this investor series. OBIS Cognition™ remains separately governed and is not consolidated as a commercial profit platform; PBN/NCS remains separately governed long-horizon optionality unless a dedicated investment perimeter is approved.

Valuation & Capital Formation

The current investment logic links a provisional enterprise value reference to a focused seed round intended to reduce specific uncertainties.

CURRENT PRE-MONEY VALUATION

Current Pre-Money value: US\$5.448 billion. The estimate is anchored primarily in the documented LPS™ and SPI™ economics and is strengthened by broader biotechnology platform optionality, corporate readiness, IP position and milestone-linked value creation.

US\$1.2M seed allocation

Use of funds	Amount	Share
Early R&D & proof of concept	US\$400k	33.3%
Regulatory & quality preparation	US\$200k	16.7%
Minimum team & operations	US\$200k	16.7%
Corporate/legal/tax/financial	US\$150k	12.5%
IP protection strategy	US\$150k	12.5%
Central contingency	US\$60k	5.0%
Investor materials / data room	US\$40k	3.3%

Capital asymmetry

The seed round is small relative to the current US\$5.448B Pre-Money valuation and modeled market scale. Its purpose is not broad commercialization; it is to convert selected corporate, IP, technical, regulatory and execution uncertainties into defined evidence and readiness for later institutional capital.

Financing discipline

The 2027 seed framework does not automatically select preferred equity, SAFE, convertible note or another instrument. Security, ownership, governance and closing terms remain transaction-specific and subject to professional review.

Intellectual Property, Collaboration & Governance

Protected Background IP and transaction-specific rights are central to how OBIS intends to preserve platform value while expanding external capability.

Priority IP workstreams

LPS™, PAK™, CMPT™ and SPI™ are the first four provisional filing workstreams in the current roadmap.

Background IP

Pre-existing OBIS architecture, concepts, documentation and know-how remain a defined ownership layer and are not transferred by association.

Controlled disclosure

Investor and collaborator materials remain at the level required to understand rationale, status, economics and development logic without revealing replicable enabling formulation details.

Patent Pending discipline

The term “Patent Pending” is used program-by-program only after the corresponding application has actually been filed.

Foreground / Project IP


Rights arising from collaborative work are determined by actual inventorship, contributions, contracts and applicable institutional policies.

Separate collaboration channels

Scientific leadership, sponsored research, investment, licensing/co-development and business development use distinct instruments and economics.

Strategic Collaboration Architecture

Distinct channels. Separate economics. Defined rights.



Governance principle


An investment is not a licence. Research funding is not automatically equity consideration. A scientific appointment does not transfer corporate control or Background IP. Commercial rights exist only to the extent expressly negotiated and documented.

Milestones & Value Inflection – 2027–2034

The financing thesis is strongest when capital is linked to measurable reductions in scientific, IP, regulatory and execution risk.

2027–2034 Value-Inflection Roadmap

Capital and value advance through evidence, protection, regulatory clarity, partnering and scale.



Seed milestone gates

The current seed architecture uses a progression from preparation and protection through proof-of-concept, regulatory/quality readiness and Series A preparation. Capital deployment is governed by evidence, acceptance criteria, documented decisions and the ability to continue, repeat, defer or stop work when warranted.

- IP protection and controlled disclosure improve defensibility before broader technical engagement.
- Reproducible proof-of-concept can materially reduce scientific uncertainty and improve program prioritization.
- Regulatory and quality readiness increase visibility into execution requirements, cost and timeline.
- External validation and strategic transactions can provide market confirmation beyond internal projections.
- Manufacturing, delivery and scale readiness determine whether modeled economics can translate into executable commercialization.

Investor Reading Guide & Diligence Logic

The series is designed for controlled review: broad enough for investment analysis, but segmented so that scientific, financial and proprietary questions can be examined without unnecessary disclosure.

Investor question	Primary documents	What they answer
Investment thesis / current value	Documents 1 & 5	Executive logic and current US\$5.448B Pre-Money standard
Flagship economics	Documents 2 & 3	LPST [™] and SPI [™] market, scenario and value-creation models
Portfolio breadth	Document 4	72-product / six-generation architecture, prioritization and partnering optionality
Capital structure / deployment	Documents 6 & 7	US\$1.2M financing structure, uses, milestones and value inflection
IP ownership / filing roadmap	Document 8	Background IP, priority provisional workstreams and Patent Pending controls
Collaboration / transaction boundaries	Document 9	Research, investment, licensing, governance and economic separation

Controlled diligence principle

The core investor series is a decision framework, not a substitute for the underlying data room. Program-specific scientific, technical, corporate, IP, financial and regulatory source documents can be provided under the appropriate level of confidentiality when a qualified reviewer requires deeper validation.

Source-control rule

2027 is the common external identity of the series. Current corporate facts are separated from forward-looking models. Revenue scenarios are not enterprise valuation. LPST[™], SPI[™] and portfolio-level economics are not double-counted. The approved 2027 valuation, seed terms and scenario assumptions should remain under version control.

Update cycle

This introductory synthesis and the nine specialized documents are scheduled for comprehensive review and update in 2028, incorporating the scientific, financial, regulatory, corporate, IP and partnership milestones achieved during 2027.

Executive Investment Case – 2027

A concise closing statement for the complete OBIS Financial & Strategic Investment Series – 2027.

THE CASE

OBIS presents an early-stage biotechnology investment proposition built around a focused flagship commercial case, a high-impact immunoprotection program, a 72-product platform across six generations, developing intellectual-property protection, a defined US\$1.2M seed requirement and multiple routes to scientific validation, licensing, co-development, strategic investment and institutional collaboration.

CURRENT VALUE REFERENCE

Current Formula-Driven Pre-Money Valuation: US\$5.448 billion. This figure is a current working estimate and is the current model-derived standard and is recalibrated when material scientific, regulatory, financial or transactional variables change.

What the 2027 series establishes

- A single executive financial and strategic narrative across nine specialized documents.
- Clear separation between product-market scenarios, platform optionality and corporate valuation.
- A seed financing architecture tied to concrete de-risking outputs rather than generalized spending.
- A protected IP and disclosure perimeter designed to preserve Background IP and future transaction value.
- A collaboration framework that can add scientific, institutional and financial capability without automatic transfer of unrelated rights.
- **A milestone-based pathway from 2027 definition and protection toward evidence, partnering, scale and the 2027–2034 planning horizon.**

Series status

Executive introduction to the OBIS Financial & Strategic Investment Series – 2027. Current figures are investor-analysis models and the current model-derived valuation standard, not audited historical results, contracts or guarantees. Next comprehensive review: 2028.

OBIS Innovation & Solutions Inc.
One Vision. Three Paradigms. A Shared Future.